Oculis Announces Public Listing After Completing Business Combination Between European Biotech Acquisition Corp. And Oculis SA

CFGI’s Capital Markets team assisted Oculis Holding AG (“Oculis”) with its listing on Nasdaq after successfully closing the business combination between European Biotech Acquisition Corp.

More

Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market

CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.

More

Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.

CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.

More

BCP Raptor Holdco LP Completes Reverse Merger With Altus Midstream Company

CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.

More

The Future Is Already Here, and CFOs Need to Transform Finance to Survive

Download the Whitepaper

2021 Year in Review

2021 was a year of tremendous change and growth for CFGI.

More

Capital Markets Advisory: 2021 Year in Review

2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.

More

CFGI Celebrates Largest Promotion Class for 2022

2021 was an exciting year for CFGI; we announced a new partnership with CVC alongside current partner The Carlyle Group, saw significant growth in the business and can now announce the largest promotion class to date.

More

Enjoy Technology Completes Business Combination With Marquee Raine Acquisition Corp.

CFGI’s Capital Markets team assisted Enjoy Technology, Inc.

More